Quote
1060.84
-11.16 (-1.04%)
We have scored 56 news catalysts on MCK (MCK) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in sector healthcare and eps growth rate.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
1046.70–1070.14
Open
1051.67
Prev close
1072.00
Volume
809.8K
Avg volume
—
Dividend
—
IPO
—
No scored news tagged MCK or its network in the window yet.
Show more MCK articles →Analysts publish price targets on MCK, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $845 to $1,050
as of 2026-09-01
The market is 8% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MCK — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MCK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The reconstruction
The price sits 8% below the median published target and at the 33rd percentile by count, meaning the market leans bearish and explicitly declines to pay for the most optimistic growth assumptions.
What the disagreement turns on
Can the Oncology & Multispecialty segment and GLP-1 distribution sustain growth fast enough to offset the priced-in deceleration of the core pharmaceutical business, and the available unit volume data can test the revenue side but cannot measure the margin impact.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $885 on 2026-09-01 — the quote has since moved +20%, so read this as a record of what was priced in then, not now.
